Biotech Values

[jbog]

Eli Lilly highlights weight loss agent’s potential in fatty liver
Jun. 27, 2023 1:03 PM ETEli Lilly and Company (LLY)MDGL, VKTX, NGM, GNFT, ETNB, IVA, TERNBy: Dulan Lokuwithana, SA News Editor1 Comment
Lilly Biotechnology Center campus of an American pharmaceutical company Eli Lilly and Company
Michael Vi

Biopharmaceutical firms focused on liver diseases trended lower Tuesday after pharma giant Eli Lilly (NYSE:LLY) announced data highlighting the potential of its weight loss candidate retatrutide in obese patients with excess liver fat.

The condition known as non-alcoholic fatty liver disease (NAFLD) affects an estimated 24% of Americans.

According to Lilly (LLY), the findings from its Phase 2 clinical trial for retatrutide indicated normalization of liver fat in nine out of 10 NAFLD patients who received the once-weekly injectable for 48 weeks at the two highest doses.

The data were part of a substudy that evaluated retatrutide, which targets GIP/GLP-1/Glucagon receptors, in 98 patients with obesity and NAFLD.

In reaction to data, companies focused on treatments for liver diseases including NAFLD fell. Notable decliners include Terns Pharmaceuticals (TERN), Viking Therapeutics (VKTX), Madrigal Pharmaceuticals (MDGL), NGM Biopharmaceuticals (NGM), 89bio (ETNB), Genfit (GNFT), and Inventiva (IVA).

https://seekingalpha.com/news/3983279-eli-lilly-shows-weight-loss-agents-potential-fatty-liver